Under construction – not a live service
Sign in
Taking people in DenmarkNo phase

Studies people with fatty liver disease and related chronic liver conditions

Collects health information and samples from adults with chronic liver disease linked to fatty liver.

Plain-language title generated from the registry record
Registry title: An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis

Key facts

Where
Hvidovre, DenmarkSee the site

Where in Denmark

  • Hvidovre University HospitalHvidovre, DenmarkTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Copenhagen
Trial code
NCT05335603
Record updated
19 April 2022
Original description
Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hereditary hemochromatosis and alpha-1-antitrypsin deficiency and may also develop secondary to other diseases like inflammatory bowel disease and chronic pancreatitis. Diagnosing chronic liver diseases can be challenging and treatment may be limited. In-depth phenotyping at a tissue level may generate insight into the underlying pathophysiology of diseases and furthermore identify common as well as specific diagnostic biomarkers and future treatment targets of the diseases. We therefore undertake a study that evaluates patients with chronic liver diseases associated with hepatic steatosis.Read full original descriptionShow less

Fatty Liver Library (FALL): a Prospective Cohort Study Evaluating the Characteristics of Chronic Liver Diseases Associated With Hepatic Steatosis

Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hereditary hemochromatosis and alpha-1-antitrypsin deficiency and may also develop secondary to other diseases like inflammatory bowel disease and chronic pancreatitis. Diagnosing chronic liver diseases can be challenging and treatment may be limited. In-depth phenotyping at a tissue level may generate insight into the underlying pathophysiology of diseases and furthermore identify common as well as specific diagnostic biomarkers and future treatment targets of the diseases. We therefore undertake a study that evaluates patients with chronic liver diseases associated with hepatic steatosis.

Inclusion: Adult patients/healthy control participants (age 18 or above) who can give their informed consent; Suspected liver disease:; non-alcoholic steatohepatitis; alcoholic steatohepatitis; autoimmune hepatitis; primary biliary cholangitis; primary sclerosing cholangitis; inflammatory bowel disease; polycystic ovary syndrome; hereditary haemochromatosis; chronic pancreatitis; cystic fibrosis; alpha-1 antitrypsin deficiency.

Exclusion: malignant diseases; viral hepatitis; Patients with:; human immunodeficiency virus; contraindications to liver biopsy.

ClinicalTrials.gov NCT05335603